Article

OVD dual pack gets FDA approval

Abbott has received FDA approval for its Healon Duet Dual Pack OVD, which includes Healon and Healon EndoCoat OVDs in separate sterile trays.

 

Abbott Park, IL-Abbott has received FDA approval for its Healon Duet Dual Pack ophthalmic viscosurgical device (OVD). The pack includes Healon (high viscosity) and Healon EndoCoat (dispersive) OVDs in separate sterile trays within one package to allow physicians to streamline their cataract surgery setup.

“The U.S. approval of the [dual pack] adds to Abbott’s reliable portfolio of OVD offerings that have been used for more than 25 years worldwide,” said Murthy Simhambhatla, senior vice president, Abbott Medical Optics. “Now delivered together, [the two OVDs] offer the cataract surgeon outstanding protection, control, clarity, and ease-of-use during each step of the procedure.”

To learn more about Abbott's family of Healon OVDs, visit www.abbottmedicaloptics.com.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
© 2025 MJH Life Sciences

All rights reserved.